NY-IHS
12.11.2021 12:23:05 CET | Business Wire | Press release
Innovative Health Sciences, LLC (“IHS” or the “Company”) will be presenting its breakthrough versatile and low cost non-electric infusion system at Medica, a world-renowned trade fair for medical devices and medical technologies, November 15 – November 18. IHS Director of European Sales, Nektarios Manatos will be showcasing the Insignis™ Syringe Infusion System in Hall 6, booth B80 alongside Assut Europe SpA.
The Insignis™ Syringe Infusion System is the first combination of intravenous and subcutaneous non-electric infusion pump created for use with a selectable rate flow controller, the IV Controller and the OneSett™. The transformative Insignis™ System for intravenous administration answers the world-wide need for a portable, non-electric, versatile, cost-effective, and intuitive infusion pump to accurately deliver medications from KVO up to 250ml/hr with a direct reading selectable rate flow controller.
“Medica is a great opportunity for IHS to introduce the Insignis™ family of products to the industry – it’s a place where cutting edge medical technologies and groundbreaking innovation are center stage,” says Andrew Sealfon, Chairman, Founder, and Chief Technology Officer. “It’s the perfect setting for IHS to showcase our products.” IHS has worked tirelessly to improve infusion technologies and is excited to bring this new medical paradigm to the infusion industry.
IHS received CE Certification for the Insignis™ Syringe Infusion System earlier this year, which enables sales in the European Union. The Insignis –26G™ Subcutaneous Needle Sets are FDA cleared in the U.S. and IHS expects to receive full regulatory clearance for the entire Insignis™ system in the next few weeks.
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion. For more information on the Company and the products, be sure to check out the new website, www.innohealthsci.com .
Forward-Looking Statements
The statements contained herein are not guaranteed of future performance and undue reliance should not be placed on them. Such Forward-Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward-Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005509/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 19:00:00 CEST | Press release
Court orders Siemens to halt production and recall and destroy products across Germany, France and the Netherlands Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1
RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 18:30:00 CEST | Press release
Wavecrest Growth Partners invests to enable combination and support growth of the combined company RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, d
Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 17:42:00 CEST | Press release
Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop
IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program16.6.2026 17:00:00 CEST | Press release
A pioneering perfumery program that develops industry-ready talent IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to date, and a 100% job landing rate up to six months after graduation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615461626/en/ The IFF ISIPCA Scent Design and Creation program has been pioneering fragrance education and excellence since 2016. “Over the past decade, IFF ISIPCA has built a strong pipeline of diverse, high-potential fragrance experts, combining creative excellence, scientific expertise and a
Fenchurch Advisory Partners to Combine With Broadhaven Capital Partners, Creating the Preeminent International Investment Bank Serving the Financial Services Sector16.6.2026 16:30:00 CEST | Press release
Fenchurch Advisory Partners has entered into a definitive agreement to combine with Broadhaven Capital Partners, a leading independent advisory firm to the financial technology and financial services sectors in North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616214669/en/ Fenchurch is one of the most respected investment banking advisory firms dedicated exclusively to the financial services sector. With offices in London, New York and Paris, Fenchurch provides trusted, independent advice to corporates and financial sponsors across insurance, asset and wealth management, banking, and specialty finance. In 2025, Fenchurch advised on 27 transactions, ranking as the number one adviser to the financial services sector in the UK and Europe. Founded in 2009, Broadhaven has established itself as a premier investment bank advising corporates and financial sponsors on M&A, capital raising, and strategic transactions,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom